Cargando…
Considerations Regarding Public Use of Longevity Interventions
Public attention and interest for longevity interventions are growing. These can include dietary interventions such as intermittent fasting, physical interventions such as various exercise regimens, or through supplementation of nutraceuticals or administration of pharmaceutics. However, it is unlik...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261328/ https://www.ncbi.nlm.nih.gov/pubmed/35821857 http://dx.doi.org/10.3389/fragi.2022.903049 |
_version_ | 1784742252593020928 |
---|---|
author | Liu, Yasmine J. McIntyre, Rebecca L. Janssens, Georges E. |
author_facet | Liu, Yasmine J. McIntyre, Rebecca L. Janssens, Georges E. |
author_sort | Liu, Yasmine J. |
collection | PubMed |
description | Public attention and interest for longevity interventions are growing. These can include dietary interventions such as intermittent fasting, physical interventions such as various exercise regimens, or through supplementation of nutraceuticals or administration of pharmaceutics. However, it is unlikely that most interventions identified in model organisms will translate to humans, or that every intervention will benefit each person equally. In the worst case, even detrimental health effects may occur. Therefore, identifying longevity interventions using human data and tracking the aging process in people is of paramount importance as we look towards longevity interventions for the public. In this work, we illustrate how to identify candidate longevity interventions using population data in humans, an approach we have recently employed. We consider metformin as a case-study for potential confounders that influence effectiveness of a longevity intervention, such as lifestyle, sex, genetics, age of administration and the microbiome. Indeed, metformin, like most other longevity interventions, may end up only benefitting a subgroup of individuals. Fortunately, technologies have emerged for tracking the rate of ‘biological’ aging in individuals, which greatly aids in assessing effectiveness. Recently, we have demonstrated that even wearable devices, accessible to everyone, can be used for this purpose. We therefore propose how to use such approaches to test interventions in the general population. In summary, we advocate that 1) not all interventions will be beneficial for each individual and therefore 2) it is imperative that individuals track their own aging rates to assess healthy aging interventions. |
format | Online Article Text |
id | pubmed-9261328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92613282022-07-11 Considerations Regarding Public Use of Longevity Interventions Liu, Yasmine J. McIntyre, Rebecca L. Janssens, Georges E. Front Aging Aging Public attention and interest for longevity interventions are growing. These can include dietary interventions such as intermittent fasting, physical interventions such as various exercise regimens, or through supplementation of nutraceuticals or administration of pharmaceutics. However, it is unlikely that most interventions identified in model organisms will translate to humans, or that every intervention will benefit each person equally. In the worst case, even detrimental health effects may occur. Therefore, identifying longevity interventions using human data and tracking the aging process in people is of paramount importance as we look towards longevity interventions for the public. In this work, we illustrate how to identify candidate longevity interventions using population data in humans, an approach we have recently employed. We consider metformin as a case-study for potential confounders that influence effectiveness of a longevity intervention, such as lifestyle, sex, genetics, age of administration and the microbiome. Indeed, metformin, like most other longevity interventions, may end up only benefitting a subgroup of individuals. Fortunately, technologies have emerged for tracking the rate of ‘biological’ aging in individuals, which greatly aids in assessing effectiveness. Recently, we have demonstrated that even wearable devices, accessible to everyone, can be used for this purpose. We therefore propose how to use such approaches to test interventions in the general population. In summary, we advocate that 1) not all interventions will be beneficial for each individual and therefore 2) it is imperative that individuals track their own aging rates to assess healthy aging interventions. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9261328/ /pubmed/35821857 http://dx.doi.org/10.3389/fragi.2022.903049 Text en Copyright © 2022 Liu, McIntyre and Janssens. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Aging Liu, Yasmine J. McIntyre, Rebecca L. Janssens, Georges E. Considerations Regarding Public Use of Longevity Interventions |
title | Considerations Regarding Public Use of Longevity Interventions |
title_full | Considerations Regarding Public Use of Longevity Interventions |
title_fullStr | Considerations Regarding Public Use of Longevity Interventions |
title_full_unstemmed | Considerations Regarding Public Use of Longevity Interventions |
title_short | Considerations Regarding Public Use of Longevity Interventions |
title_sort | considerations regarding public use of longevity interventions |
topic | Aging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261328/ https://www.ncbi.nlm.nih.gov/pubmed/35821857 http://dx.doi.org/10.3389/fragi.2022.903049 |
work_keys_str_mv | AT liuyasminej considerationsregardingpublicuseoflongevityinterventions AT mcintyrerebeccal considerationsregardingpublicuseoflongevityinterventions AT janssensgeorgese considerationsregardingpublicuseoflongevityinterventions |